WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H562937
CAS#: 251963-74-3
Description: L-708906 is an inhibitor of Human Immunodeficiency Virus Type 1 (HIV-1).
Hodoodo Cat#: H562937
Name: L-708906
CAS#: 251963-74-3
Chemical Formula: C24H20O6
Exact Mass: 404.13
Molecular Weight: 404.410
Elemental Analysis: C, 71.28; H, 4.98; O, 23.74
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: L-708906; L 708906; L708906; ARRY142886; ARRY-142886; ARRY 142886;
IUPAC/Chemical Name: 4-[3,5-Bis(phenylmethoxy)phenyl]-2,4-dioxobutanoic acid
InChi Key: SLRLQBRWUMWEOZ-UHFFFAOYSA-N
InChi Code: InChI=1S/C24H20O6/c25-22(14-23(26)24(27)28)19-11-20(29-15-17-7-3-1-4-8-17)13-21(12-19)30-16-18-9-5-2-6-10-18/h1-13H,14-16H2,(H,27,28)
SMILES Code: O=C(O)C(CC(C1=CC(OCC2=CC=CC=C2)=CC(OCC3=CC=CC=C3)=C1)=O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 404.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Beare KD, Coster MJ, Rutledge PJ. Diketoacid inhibitors of HIV-1 integrase: from L-708,906 to raltegravir and beyond. Curr Med Chem. 2012;19(8):1177-92. Review. PubMed PMID: 22214459.
2: Barreca ML, Iraci N, De Luca L, Chimirri A. Induced-fit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors. ChemMedChem. 2009 Sep;4(9):1446-56. doi: 10.1002/cmdc.200900166. PubMed PMID: 19544345.
3: Chi G, Nair V, Semenova E, Pommier Y. A novel diketo phosphonic acid that exhibits specific, strand-transfer inhibition of HIV integrase and anti-HIV activity. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1266-9. Epub 2006 Dec 15. PubMed PMID: 17188872; PubMed Central PMCID: PMC1839884.
4: Johnson AA, Marchand C, Pommier Y. HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial. Curr Top Med Chem. 2004;4(10):1059-77. Review. PubMed PMID: 15193139.
5: Fikkert V, Van Maele B, Vercammen J, Hantson A, Van Remoortel B, Michiels M, Gurnari C, Pannecouque C, De Maeyer M, Engelborghs Y, De Clercq E, Debyser Z, Witvrouw M. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J Virol. 2003 Nov;77(21):11459-70. PubMed PMID: 14557631; PubMed Central PMCID: PMC229256.
6: Neamati N. Dipyrimidine-based inhibitors of HIV-1 integrase. Expert Opin Investig Drugs. 2003 Feb;12(2):289-92. Review. PubMed PMID: 12556222.
7: Pluymers W, Pais G, Van Maele B, Pannecouque C, Fikkert V, Burke TR Jr, De Clercq E, Witvrouw M, Neamati N, Debyser Z. Inhibition of human immunodeficiency virus type 1 integration by diketo derivatives. Antimicrob Agents Chemother. 2002 Oct;46(10):3292-7. PubMed PMID: 12234864; PubMed Central PMCID: PMC128766.
8: Rao GS, Bhatnagar S, Ahuja V. Structure-based design of a novel peptide inhibitor of HIV-1 integrase: a computer modeling approach. J Biomol Struct Dyn. 2002 Aug;20(1):31-8. PubMed PMID: 12144350.
9: Pais GC, Zhang X, Marchand C, Neamati N, Cowansage K, Svarovskaia ES, Pathak VK, Tang Y, Nicklaus M, Pommier Y, Burke TR Jr. Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors. J Med Chem. 2002 Jul 18;45(15):3184-94. PubMed PMID: 12109903.
10: Marchand C, Zhang X, Pais GC, Cowansage K, Neamati N, Burke TR Jr, Pommier Y. Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. J Biol Chem. 2002 Apr 12;277(15):12596-603. Epub 2002 Jan 22. PubMed PMID: 11805103.
11: Vandegraaff N, Kumar R, Hocking H, Burke TR Jr, Mills J, Rhodes D, Burrell CJ, Li P. Specific inhibition of human immunodeficiency virus type 1 (HIV-1) integration in cell culture: putative inhibitors of HIV-1 integrase. Antimicrob Agents Chemother. 2001 Sep;45(9):2510-6. PubMed PMID: 11502522; PubMed Central PMCID: PMC90685.
12: Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, Espeseth A, Gabryelski L, Schleif W, Blau C, Miller MD. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000 Jan 28;287(5453):646-50. PubMed PMID: 10649997.